Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Conditions: Non-small Cell Lung Cancer Interventions: Drug: sunvozertinib in combination with Anlotinib Sponsors: Hunan Province Tumor Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials